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Abstract The mechanistic study of glaucoma pathogenesis
has shifted to seeking to understand the effects of immune
responses on retinal ganglion cell damage and protection.
Cytokines are the hormonal factors that mediate most of the
biologicaleffectsinboththeimmuneandnonimmunesystems.
CD4-expressing T helper cells are a major source of cytokine
production and regulation. Type 1 helper T (Th1) cells are
characterized by the production of proinflammatory cytokines
suchasinterferon-gamma,interleukin(IL)-2,IL-12,IL-23,and
tumor necrosis factor-alpha while type 2 helper T (Th2) cells
are characterized by the production of IL-4, IL-5, IL-6, and IL-
10. The balance of Th1/Th2 cytokine production influences
many pathological processes and plays both causative and
protective roles in neuronal damage. Growing evidence
indicates that imbalances of Th1/Th2 cytokine production are
involved in neural damage or protection in many neurological
diseases. In this review, we discuss the possible roles of Th1/
Th2 cytokine production and imbalance of Th1/Th2 cytokines
in retina, especially glaucomatous optic neuropathy.
Keywords Glaucoma.Cytokines.Neuropathy.
Neuroprotection
Introduction
Glaucoma is one of the leading causes of vision loss as a
result of impairment of retina ganglion cells (RGCs).
Although lowering of intraocular pressure (IOP) is currently
the method of choice for the treatment of glaucoma,
glaucomatous neuropathy may still develop and lead to loss
of vision [1]. There are no other effective therapeutic and/or
preventive interventions. Other mechanisms, besides the
increase in IOP, have been associated with degeneration of
RGCs. These include ischemia, glutamate excitotoxic stress,
high reactive oxygen species production, and the loss of
mitochondrial function. Recent mechanistic studies have
focused on immunological changes during glaucomatous
pathogenesis and possible preventive therapies [2]. The
major targets of interest are cytokines and their functions in
damage or protection of retinal ganglion cells. Recent
advances in the studies of glaucoma or RGCs reveal that
cytokines are a possible factor in the pathogenesis of
glaucoma and may regulate RGCs survival or death. Here,
we will review the roles of both type 1 helper T (Th1)-
derived and type 2 helper T (Th2)-derived cytokines in the
damage or protection of RGCs and the possible relationship
of these cytokines with human glaucoma.
Cytokines from T helper cells and neuronal diseases
CD4-expressing T helper cells develop into two major
subtypes of cells known as Th1 and Th2 cells [3, 4]. The
two subtypes produce different sets of cytokines, which are
involved in many physiological and pathological processes
in humans. It has been considered that Th1 cells are
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kines such as IFN-γ, IL-2, IL-12, IL-23, and TNF-alpha
while Th2 cells are characterized by the production of IL-4,
IL-5, IL-6, and IL-10 (Fig. 1). We now know that this
classification is an oversimplification, and that the effects of
cytokines are far more complicated in the tissue and cells in
response to stress.
The functions of T helper cytokines have been exten-
sively studied in a number of different conditions [5, 6],
including neural damage and protection. In the autoimmune
central nervous system disease multiple sclerosis and its
animal model experimental autoimmune encephalomyelitis
(EAE), T helper lymphocytes play a crucial role in
inflammatory tissue damage to the neurons [7]. Cytokines,
such as interferon-gamma, are also involved in neuron
damage resulting from nonautoimmune conditions such as
ischemia [8] and a number of neurodegenerative diseases
[9]. In contrast, T helper cytokines can also play significant
roles in protection against neural cell death [10], indicating
two aspects of cytokine function, namely, in neural damage
and protection.
Cytokines play essential roles in retina neural damage
The causes of RGC death have been studied in many model
systems in vitro and in vivo, including glutamate or N-
methyl-D-aspartate (NMDA) ocular injection and cytotox-
icity, increase of intraocular pressure (IOP), ischemia/
reperfusion (I/R), axotomy of optic nerves, optic nerve
crush, experimental autoimmune uveoretinitis (EAU), EAE,
and serum deprivation in cultured neural cells. Evidence
over the past decade has revealed that cytokines produced
from both Th1 and Th2 cells were involved in RGCs death
in response to the insults listed above. Detailed information
is listed in Table 1.
Increased levels of Th1 cytokines, such as IFN-gamma
[11], IL-1 [12], IL-2 [13], IL-17 [13], and TNF-alpha [11,
13–18] were reported to be significantly associated with
retina and RGC damage caused by distinct insults in vivo
and in vitro, while IL-6 is the only Th2 cytokine that has
been reported to show similar results [11, 19]. Most work
has been focused on the actions of TNF-alpha. TNF-alpha
was first found elevated in retina following increase of
hydrostatic pressure. RGC apoptosis rates were attenuated
approximately 66% by neutralizing antibody against TNF-
alpha [14]. An increase of TNF-alpha expression has been
associated with the most severely damaged optic nerve
heads from human glaucomas [15], indicating that TNF-
alpha contributes to the progression of optic nerve
degeneration in this disease. Later work has confirmed that
TNF-alpha is a critical cytokine in RGC damage caused by
different insults, such as EAU [13], optic nerve crush [20],
and serum withdrawal [11] in vitro. Direct ocular injection
of TNF-alpha [16] in vivo also results in RGC death.
The Th2 cytokine IL-6 is a member of a large cytokine
family that triggers the gp130 receptor and activates signal
transducer and activator of transcription 1 (STAT1) and
STAT3 in response to stress [21]. IL-6 has been considered
a neurotrophic factor in protection of neurons from damage
in many neural degenerative conditions [22, 23]. While IL-
6 can play a neuroprotective role in retina, as described
below, it has been shown to be involved in retina or RGC
damage under a number of different conditions [11, 19]. In
a study of Rho-kinase inhibition on retinal cell survival, the
reduction of proinflammatory cytokines including TNF-
alpha, IFN-gamma, and IL-6 likely contributed to the
significantly lower toxicity on retina explants [11]. Other
evidence showed that IL-6 deficiency could increase the
rate of RGC survival during the first 24 h after optic nerve
injury [19], indicating the complexity of IL-6 in both retina
damage and protection.
IL-17 is produced by Th17 cells. This cell type can be
stimulated to expand by IL-2 and IL-23. Besides IL-17
production, Th17 cells also secrete IL-6 and TNF-alpha and
now are recognized as causative agents of several diseases
previously attributed to Th1 cells, such as chronic inflam-
matory bowel disease [24]. IL-17 is an agent that contrib-
utes to retina damage in an EAU model [13]. Retinal
damage in this model can be reduced by a neutralized by
specific anti-IL-17 antibody.
Cytokines in retina neural protection
A significant number of studies on cytokine protection of
neurons have been performed and these numbers are
Fig. 1 Th1 and Th2 cytokine signaling and T helper cells. Th1 and
Th2 cells can be induced from Th0 cells by IL-12 and IL-4,
respectively. IL-2 promotes Th0 cell and also Th1 and Th2 cell
proliferation. The major cytokines produced by Th1 or Th2 cells are
listed
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damage, many kinds of insults have been used to test the roles
of cytokines in protection of retinal neurons both in vivo and
in vitro. In an EAU model, IL-27 and IFN-gamma have been
shown to inhibit IL-2-induced expansion of IL-17, produced
by Th17 cells, and to ameliorate retina damage by EAU [13].
This indicates that Th1 cytokines such as IFN-gamma could
have protective roles on neurons under certain circum-
stances. In a similar case, IL-1, a mediator of neural injury,
has a protective role by preventing neuronal cell death from
glutamate neurotoxicity [25]. TNF-alpha, a clear mediator
for neural damage, also can prevent secondary death of
RGCs after axotomy of the optic nerve in vivo [26].
Th2 cytokines such as IL-4, IL-6, and IL-10 show
neuroprotective functions in many different types of RGC
injury such as optic nerve axotomy [27] and ischemia/
reperfusion [28] in vivo and serum deprivation [29] in vitro
(Table 2). Intraocular administration of adenoviral vectors
encoding IL-10 and IL-4 may help prevent neurodegenera-
tion caused by the activation of glial cells postaxotomy
[27]. IL-6 is upregulated after retinal ischemia/reperfusion
injury, and its expression by microglia/phagocytic cells may
protect neurons in the RGC layer from this insult.
Exogenously added IL-6 protects the inner retina after
ischemia/reperfusion injury [28]. Our studies on STAT3
[30], the downstream effector of IL-6 and IL-10, have
shown that STAT3 activation is essential for RGC survival,
and persistent activation of STAT3 by neurotrophic factors
and cytokines provides strong neuroprotection. This sug-
gests that STAT3 activation will be an effective strategy in a
number of chronic retinal diseases.
Cell-mediated immunity and inflammatory responses are
also thought to be involved in neural damage and
protection. There is evidence that inflammatory leukocyte
recruitment can play a causative role in RGC cell death in
NMDA-induced excitotoxicity. Anti-inflammatory agents
improved RGC survival [31], suggesting that increases in
inflammatory responses can lead to neural damage. On the
other hand, an evoked T cell-dependent response has been
shown to help neuron survival [32]. It was reported that
using a single low dose of whole-body or lymphoid-organ
gamma-irradiation significantly increased T cell-dependent
responses, and this improved the spontaneous recovery of
neurodegenerative conditions caused by injection of a toxic
dose of intraocular glutamate [33]. Animals with severe
immune deficiency or deprived of mature T cells were
unable to benefit from this treatment [33], suggesting that
this neuroprotection is immune mediated.
Cytokines in glaucomatous optic neuropathy
Alterations of cytokines in human glaucoma have been
studied for over three decades. Fibroblasts from Tenon’s
capsule are cellular components that contribute to unsuc-
cessful glaucoma filtration surgery. Using the materials
from Tenon’sc a p s u l e[ 34], many studies have been
performed with examination of IFN signaling including
IFN-alpha, IFN-beta, and IFN-gamma. As shown in Table 3,
both IFN-alpha2b [35] and IFN-gamma [36] inhibit the
fibroblast proliferation from Tenon’s capsule in vitro. More
recently, IL-1 has been linked to an increase in extracellular
Table 1 Cytokines in retina neural damages
Cytokines Systems Methods Cell types Insults Results Author Year
IFN-g Animals In vitro Retina explants Serum deprivation RGC damage Tura 2009
IL-1b Animals In vitro RGC Survival RGC damage Abcouwer 2008
Animals In vivo RGC NMDA RGC damage Kitaoka 2007
Animals In vivo RGC I/R RGC damage Zhang 2004
Animals In vivo RGC I/R RGC damage Yoneda 2001
IL-2 Animals In vivo Retina EAU Retina damage Amadi-Obi 2007
IL-6 Animals In vitro Retina explants Serum deprivation RGC damage Tura 2009
Animals In vivo RGC Glutamate toxicity RGC damage Fisher 2001
IL-17 Animals In vivo Retina EAU Retina damage Amadi-Obi 2007
TNF-a Animals In vivo Retina EAU Retina damage Amadi-Obi 2007
Animals In vitro Retina Serum deprivation RGC damage Tura 2009
Animals In vitro Retina explants Culture RGC damage Hong 2009
Animals In vivo RGC IOP RGC damage Nakazawa 2006
Animals In vivo RGC TNF-a injection RGC damage Kitaoka 2006
Animals In vitro RGC Survival RGC damage Tezel 2000
Human In vivo Optic nerve Expression Optic nerve damage Yuan 2000
TNFR-1 Animals In vivo RGC Optic nerve crush RGC damage Tezel 2004
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1beta each individually can increase MMP-3 expression in
the trabecular meshwork [37], and this affected the aqueous
humor outflow facility. TNF-alpha, in combination with IL-
1alpha or IL-1beta, produced intense synergistic increases
in MMP-3 and MMP-12 but not in MMP-9. These results
suggested a relationship between cytokines and glaucoma
pathogenesis.
Recent work has focused on the relationship between
cytokine production and glaucomatous optic neuropathy.
Table 3 Cytokines in human glaucoma studies
Cytokines Systems Methods Cell types Results Author Year
IFN-a2b Human In vitro Tenon’s capsule fibroblasts Inhibit cell proliferation Gillies 1993
IFN-g Human In vitro Tenon’s capsule fibroblasts Inhibit collagen synthesis Nguyen 1994
IFN-g Human In vivo Blood serum No change in glaucoma Huang unpublished
IL-1 Animals and Human In vitro Trabecular meshwork Increase MMP-3 MMP-12 Kelly 2007
IL-1 Human In vitro Trabecular meshwork ELAM-1 Wang 2001
IL-1 Human In vitro Trabecular meshwork p38 or JNK activation Zhang 2006
IL-2 Human In vivo Blood serum No change in glaucoma Yang 2001
IL-2 Human In vivo Blood serum No change in glaucoma Huang unpublished
sIL-2R Human In vivo Blood serum High in glaucoma Yang 2001
sIL-2R Human In vivo Blood serum No change in glaucoma Huang unpublished
IL-4 Human In vivo Blood serum High in glaucoma Huang unpublished
IL-6 Human In vivo Blood serum Low in glaucoma Huang unpublished
IL-10 Human In vivo Blood serum High in glaucoma Yang 2001
IL-12p40 Human In vivo Blood serum High in glaucoma Huang unpublished
IL-12p70 Human In vivo Blood serum No change in glaucoma Huang unpublished
IL-23 Human In vivo Blood serum Low in glaucoma Huang unpublished
TNF-a Animals and Human In vivo Trabecular meshwork Increase MMP-3 MMP-12 Kelley 2007
TNF-a Human In vitro Optic nerve High in glaucoma Yang 2000
TNF-a Human In vitro Blood serum Low in glaucoma Huang unpublished
Table 2 Cytokines in retina neural protection
Cytokines Systems Methods Cell types Insults Results Author Year
IFN-b1a Animals In vivo Optic nerve EAE Optic nerve protection Sättler 2006
IFN-b1b Animals In vivo RGC EAE RGC protection Maier 2006
IFN-g Animals In vivo/in vitro Retina EUA Retina protection Amadi-Obi 2007
IL-1 Animals In vitro Glail cell Glutamate toxicity RGC protection Namekata 2008
IL-1b Animals In vivo RGC Axotomy RGC protection Diem 2003
IL-2 Animals In vitro RGC Survival RGC protection Sholl-Franco 2001
IL-4 Animals In vivo RGC Axotomy RGC protection Koeberle 2004
Animals In vitro RGC Survival RGC protection Sholl-Franco 2001
IL-6 Animals In vivo RGC I/R RGC protection Sanchez 2003
Animals In vitro RGC Survival RGC protection Mendonça Torres 2001
IL-10 Animals In vivo RGC Axotomy RGC protection Koeberle 2004
Animals In vitro RGC Serum deprivation RGC protection Boyd 2003
IL-27 Animals In vivo Retina EAU Retina protection Amadi-Obi 2007
STAT3 Animals In vitro/in vivo RGC I/R and Glutamate toxicity RGC protection Zhang 2008
TNF-a Animals In vivo RGC Axotomy RGC protection Diem 2001
Leukocyte recruitment Animals In vivo RGC NMDA RGC protection Nakazawa 2007
T autoimmunity Animals In vivo RGC Optic nerve crush RGC protection Kipnis 2004
T autoimmunity Animals In vivo RGC Optic nerve crush RGC protection Yoles 2001
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serum of glaucoma patients compared with their normal
controls [38, 39]. An increase in CD3(+)/CD8(+) lympho-
cytes was also associated with glaucoma, indicating that
cellular immunity plays an important role in the initiation
and/or progression of glaucomatous optic neuropathy.
Recently, we compared human serum levels of Th1 and
Th2 cytokines among two stages of primary open-angle
glaucoma (POAG) and nonglaucomatous controls (Huang
et al., unpublished data). The results showed that patients
with POAG exhibited a significant elevation of IL-4 and a
significant reduction of IL-6 compared to the control group,
while no significant differences in IL-4 and IL-6 levels
were observed between patients with severe optic neuro-
pathy and patients with mild optic neuropathy. The level of
IL-12p40 was significantly increased in patients with
POAG compared to controls, while the average levels of
IL-23 and TNF-alpha were significantly reduced in the
POAG patients groups compared with controls. (Huang et
al., unpublished data).
In conclusion
The interplay of Th1 and Th2 cytokine dynamics in retina
neural damage and protection reflect the complexity of
immune responses during glaucoma pathogenesis. Cyto-
kines under different circumstances, or actions on different
effectors such as RGC, astrocytes, microglial cells, and
Müller glial cells, may result in distinct consequences.
Although accumulated evidence has already sketched an
outline of the roles of cytokines in glaucoma, further
detailed studies will facilitate an understanding of the ways
in which they influence the pathogenesis of glaucoma.
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